Browsing Over 32 Presentations
Sort By
The concept of CDK inhibition according to the targeted CDK subtype (ID 4)
Educational session
CDK2 as the bypass kinase for CDK4/6 inhibition (ID 7)
Lecture Time
14:50 - 15:10
Speakers
- Nicholas Turner (London, GB)
Location
Auditorium, Vall d'Hebron, Barcelona, Spain
Date
23.03.2018
Time
14:30 - 16:20
CDK4 and CDK6 inhibitors in breast cancer (ID 8)
Educational session
Are all CDK 4-6 created equal? (ID 31)
Lecture Time
14:30 - 14:50
Speakers
- Giuseppe Curigliano (Milan, IT)
Session Name
Location
Auditorium, Vall d'Hebron, Barcelona, Spain
Date
24.03.2018
Time
13:30 - 15:00
Interaction between CDKs, CDKI and other targets (ID 6)
Educational session
Interaction with immune system (ID 21)
Lecture Time
10:20 - 10:40
Speakers
- Fabrice André (Villejuif, FR)
Location
Auditorium, Vall d'Hebron, Barcelona, Spain
Date
24.03.2018
Time
09:00 - 10:50
Preclinical evidence of efficacy (ID 5)
Educational session
Preclinical evidence of activity of palbociclib (ID 12)
Lecture Time
16:40 - 17:00
Speakers
- Angel Guerrero (Valencia, ES)
Session Name
Location
Auditorium, Vall d'Hebron, Barcelona, Spain
Date
23.03.2018
Time
16:40 - 18:10
Keynote lecture (ID 2)
Keynote lecture
The cell cycle regulation and biological basis of CDK inhibition (ID 1)
Lecture Time
11:45 - 12:05
Speakers
- Marcos Malumbres (Madrid, ES)
Session Name
Location
Auditorium, Vall d'Hebron, Barcelona, Spain
Date
23.03.2018
Time
11:45 - 12:30
The disappointing results of initial CDKI and their role in other disease (ID 7)
Educational session
CDKi in non-malignant diseases (ID 27)
Lecture Time
12:00 - 12:25
Speakers
- Laurent Meijer (Roscoff, FR)
Location
Auditorium, Vall d'Hebron, Barcelona, Spain
Date
24.03.2018
Time
11:10 - 12:40
Interaction between CDKs, CDKI and other targets (ID 6)
Educational session
Synthetic lethality (ID 17)
Lecture Time
09:00 - 09:20
Speakers
- Rene Bernards (Amsterdam, NL)
Location
Auditorium, Vall d'Hebron, Barcelona, Spain
Date
24.03.2018
Time
09:00 - 10:50
The concept of CDK inhibition according to the targeted CDK subtype (ID 4)
Educational session
The role of CDK4, CDK2 and CDK1 in KRas driven lung tumors: The good, the bad and the ugly (ID 8)
Lecture Time
15:10 - 15:30
Speakers
- Mariano Barbacid (Madrid, ES)
Location
Auditorium, Vall d'Hebron, Barcelona, Spain
Date
23.03.2018
Time
14:30 - 16:20
CDK4 and CDK6 inhibitors in breast cancer (ID 8)
Educational session
Q&A (ID 32)
Lecture Time
14:50 - 15:00
Session Name
Location
Auditorium, Vall d'Hebron, Barcelona, Spain
Date
24.03.2018
Time
13:30 - 15:00
Interaction between CDKs, CDKI and other targets (ID 6)
Educational session
Q&A (ID 22)
Lecture Time
10:40 - 10:50
Location
Auditorium, Vall d'Hebron, Barcelona, Spain
Date
24.03.2018
Time
09:00 - 10:50
Preclinical evidence of efficacy (ID 5)
Educational session
Preclinical evidence of activity of ribociclib (ID 13)
Lecture Time
17:00 - 17:20
Speakers
- Gustavo Baldassarre (Aviano, IT)
Session Name
Location
Auditorium, Vall d'Hebron, Barcelona, Spain
Date
23.03.2018
Time
16:40 - 18:10
The role of CDK along the mitotic process in normal and pathological condition (ID 3)
Educational session
Integration of multiple signalling pathways through control of CDK activation (ID 2)
Lecture Time
13:20 - 13:40
Speakers
- Luca Malorni (Prato, IT)
Location
Auditorium, Vall d'Hebron, Barcelona, Spain
Date
23.03.2018
Time
13:20 - 14:30